Certara, a provider of model-informed drug development and regulatory science, announced that the U.S. Food and Drug Administration (FDA) has expanded its use of the company’s physiologically based pharmacokinetic (PBPK) Simcyp population-based simulator and its pediatric and cardiac safety simulators. Under the new agreement, FDA has almost tripled its number of licenses, equipping its modeling and simulation (M&S) review team with…